Cystic Fibrosis – Opportunity Analysis and Forecasts to 2025

Gene-therapy-for-cystic-fibrosis-effective-in-miceGlobal (7MM) sales for the cystic fibrosis (CF) market are forecast by GlobalData to grow from $2.1B in 2015 to $7.6B in 2025. The majority of sales are expected to come from the US, which will represent 68% of the market by 2025. The sales growth during the 2015–2025 forecast periods will be primarily driven by the launches of Vertex’s cystic fibrosis transmembrane conductance regulator (CFTR) modulator ivacaftor/tezacaftor.

The CFTR modulator drug class is expected to grow from 43.3% of total CF drug sales in 2015 to 81.2% of total CF drug sales in 2025. Vertex Pharmaceuticals will continue to dominate the CF drug space as it has two marketed CFTR modulators and is expected to launch third CFTR modulator during the forecast period, fulfilling some of the major unmet needs of the CF population.Untitled

Major drivers of the growth of the CF market over the forecast period will include:

  • The introduction of the high-priced, disease-modifying drug Orkambi (ivacaftor + lumacaftor) in 2015, followed by the introduction of novel, high-priced, disease-modifying CFTR modulators during the forecast period.
  • The continued growth of the number of CF patients due to the overall population growth and continuously increasing life expectancy of CF patients

Major barriers to the growth of the CF market will include:

  • The high price of CFTR modulators, which may prevent their reimbursement by local health authorities and health insurance companies.

·  The complexity inherent in the pathophysiology and molecular mechanisms involved in the development of CF, which will continue to hinder the development of safe and effective agents for the management of CF.

 

OpportunityAnalyzer: Cystic Fibrosis – Opportunity Analysis and Forecasts to 2025

Report Information:
Price:
 $10,995 (Single User License)
Published: April 2017
Publisher: GlobalData
Report Format: electronic pdf
Advertisements

Asthma Therapeutics in Asia-Pacific Markets to 2023 – High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market

landscape-1446724480-g-78815666Asia-Pacific asthma therapeutics market is forecast to grow significantly over the forecast period, from $4.1 billion in 2016 to a projected value of $6 billion by 2023, at a compound annual growth rate (CAGR) of 5.4%.
The aging population is growing significantly, which will increase the asthma prevalence in the Asia-Pacific region. In addition, the severity of asthma increases with age, meaning elderly patients require more medications to control their asthma symptoms, which will drive the market. In addition to the aging population, other factors such as increases in air pollution, dust, and pollen levels also contribute to the increase in asthma prevalence. Air pollution leads to both the occurrence of the disease and its exacerbation in children, and there is growing evidence of asthma symptoms in children who live near roadways in high traffic zones (Kopnina, 2012).
Asthma

Biologics Growing in Prominence in Asthma Treatment

While the asthma market is dominated almost exclusively by small molecules, the pipeline is more varied. It consists of 65% small molecules, but there are also 67 biologics, equating to 24% of the pipeline.

The rise in biologic development is possibly due to the success of Xolair (omalizumab), one of the currently marketed monoclonal antibodies (mAb) in asthma therapeutics, which reached blockbuster status in 2014. Xolair is a recombinant humanized anti-IgE, and was the first humanized therapeutic mAb to be indicated for asthma. It was approved by the FDA in 2003 as an add-on therapy for adults and adolescents aged 12 and over with moderate-to-severe allergic asthma and symptoms not adequately controlled with inhaled corticosteroids (ICS).

The report “Asthma Therapeutics in Asia-Pacific Markets to 2023 – High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market” provides an introduction to asthma, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology and prognosis for patients. An analysis of current treatment algorithms and options is also included.

 

Report Information:
Price:
 $4,995 (Single User License)
Published: June 2017
Publisher: GBI Research
Report Format: electronic pdf

Hydropower (Large Hydro, Small Hydro and Pumped Storage) – Global Market Size, Segmentation, Investment Trends, Regulations and Key Country Analysis to 2025

hydropowerAsia-Pacific Region Contributed Substantial Hydropower Capacity Additions in 2016

Hydropower is receiving enormous support from various governments around the world in the form of favorable policies and incentives. Of all of the renewable energy sources, hydropower is one of the most widely used, as it is inexpensive and is well established. At the global level, hydropower generation accounts for 18.6% of total power generation as of 2016. The total hydropower installed capacity increased from 864 Gigawatts (GW) in 2006 to 1,211.3 GW in 2016, at a Compound Annual Growth Rate (CAGR) of 3.4%.
As of 2016, the Asia-Pacific region was the global leader with 64.1% of global hydropower annual installed capacity followed by South and Central America, Europe, Middle East and Africa (MEA) and North America. The highest capacity additions witnessed in Asia-Pacific were attributed to countries such as China, India, and Indonesia.asd

China is the largest market in terms of cumulative and annual capacity additions

China with 50.7% of annual capacity additions was the global leader in terms of capacity additions with 21.5 GW of the annual capacity in 2016. Brazil had the second largest annual installed capacity after China with a share of 8.7% in 2016. The country added 3.7 GW of the annual capacity in the same year. Brazil is followed by India with the addition of 2.1 GW of the annual capacity in 2016.

 

Hydropower (Large Hydro, Small Hydro and Pumped Storage) – Global Market Size, Segmentation, Investment Trends, Regulations and Key Country Analysis to 2025

Report Information:
Price:
 $3,995 (Single User License)
Published: March 2017
Publisher: GlobalData
Report Format: electronic pdf

Top Trends in Prepared Foods 2017: Exploring trends in meat, fish and seafood; pasta, noodles and rice; prepared meals; savory deli food; soup; and meat substitutes

foodcasebannerFood purchases are driven by Trust, Health, and Convenience

The Comfort & Uncertainty mega-trend has strong influence over food purchases, with consumers seeking familiar brands to avoid risk. This may make it very challenging for new brands to tap into the sector. While consumers like to opt for trustworthy brands, they are also heavily driven by the Health & Wellness mega-trend. It indicates that there are opportunities for well-established brands to develop products that cater to consumers’ health needs. Consumers seek simple and affordable food products, which fit their busy lifestyles while also aligning with their budget. The challenge for trusted food brands is aligning with consumer health needs while fitting consumers’ need for value and convenience.Food

Consumers’ diets are diverse, and while most claim not to follow a specific diet, there is a gradual shift occurring in response to health trends. Interestingly, 44% of consumers in Germany follow a low-meat diet, which is a significant increase from 2014 (26%). Similarly, 6% of US consumers now claim to be vegan, up from just 1% in 2014.

Consumer Behavior

  • Key meal components are the most common daily foods.
  • Pre-packed sandwiches are the least consumed prepared food item.
  • Consumers are willing to experiment with prepared food that they do not consume frequently.
  • Consumers are less experimental with staple foods such as pasta, rice, and noodles.
  • Global consumers want quality, yet are price-sensitive.

TrendSight

The prepared foods sector represents a highly dynamic space for growth as consumers’ quest for convenience and experimentation continues and evolves and ethical and healthy eating gains consumer interest. Overarching themes include the rise of meat-free diets, healthy swaps driven by ingredient-savvy consumers seeking healthy alternatives to traditional starchy food, and experimental prepared food inspired by borrowing ideas from other food categories.

 

Top Trends in Prepared Foods: Key Trends Impacting Innovation in Prepared Foods

Report Information:
Price:
 $3,450 (Single User License)
Published: June 2017
Publisher: GlobalData
Report Format: electronic pdf

Air Quality Control System for Thermal Power, Update 2016 – Market Size, Competitive Landscape, Key Country Analysis, and Forecasts to 2020

visual_apctGlobal AQCS Market to Reach $12.8 Billion by 2020

Global Air Quality Control System (AQCS) market is expected to grow between 2016 and 2020 at a CAGR of 7.19% with market value expected to reach around $12.8 billion by 2020. The main factors that will drive growth in the AQCS market toward 2020 are upcoming coal-fired plants, the adoption of emission norms and the expectation of emission norms in countries where currently there are none. Furthermore, revival of AQCS contracts is also expected to play a major role in the growth of the market.
China is expected to lead the AQCS market throughout the 2010–2020 period. It has been one of the fastest growing industrial economies in recent decades. This rapid industrialization has led to a significant increase in electricity demand in the country. This has resulted in many new power plants being set up in the country. Coal-fired plants which contribute 40% of the power installed capacity in the country produce large amounts of emissions.air portThe AQCS market is primarily driven by regulations regarding emissions control in the power sector. There is a marked increase in the demand for AQCS from the power generating industries since they have to adhere to local and federal regulations that mandate the emissions from the power plants. The growth in power demand will drive the demand for air quality control equipment. Capacity addition through coal- and gas-based power projects and stricter regulations, especially in developing countries, are some of the principal drivers for this market.

 

Power Equipment Report: Air Quality Control System for Thermal Power

Report Information:
Price:
 $3,995 (Single User License)
Published: Feb 2017
Publisher: GlobalData
Report Format: electronic pdf

Global Immunology Drugs Market to 2022 – Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth

7-730x338Global revenues for the immunology market are forecast to reach $74.1 billion in 2022, growing at a compound annual growth rate of 3.63%. When considering the market, a number of therapies have been approved for immunological disorders, including the largely genericized disease-modifying anti-rheumatic drug (DMARD) class of small molecule drugs. However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. There is currently no cure for immunological disorders due to the highly complex nature of the immune system and the fact that many components of the pathophysiological states of these diseases have roles in the healthy immune system.

Although there is a high degree of failure and uncertainty in R&D of immunological drugs, there are 2,054 drugs in active development in the immunology pipeline. In the long-term, this is expected to drive growth in this market in spite of the anticipated approval of biosimilars for key blockbuster drugs and resultant erosion of revenues. Cytokines and their receptors account for the largest single segment of each of the pipelines which make up the largest individual class.

Drug

Global Immunology Drugs Market to 2022” focuses on four key indications within immunology: Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Psoriasis and Inflammatory bowel disease (The two major types of Inflammatory bowel disease covered in this report are Ulcerative colitis and Crohn’s disease). With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in SLE, increasing the need for extensive R&D within this area.

Report Information:
Price:
 $4,995 (Single User License)
Published: May 2017
Publisher: GBI Research
Report Format: electronic pd
electronic pdf

Global Airport Retailing 2016-2021

SINGAPORE - NOVEMBER 09, 2015: interior of Changi Airport. Singapore Changi Airport, is the primaryRising Global Tourism supports recovery in Travel Retail

Despite many challenges, 2016 was a successful year for global tourism. Global outbound tourism grew by approximately 5% due to the rise in Chinese and US outbound tourism; an estimation based on the United Nations World Tourism Organization’s declaration for nine months data for 2016 where global outbound tourism grew by 4%. Europe is the most preferred destination for foreign travelers, followed by Asia-Pacific. The rise in global tourism is crucial as travel retail sales were declining due to terror threats and less spending in 2015. Increasing traffic at airports and expanding retail services are expected to result in higher sales.Air

Global airport retail sales recovered in 2016 with growth of 4.0%, having witnessed a 2.8% decline in 2015. The growth is driven by an uplift in global passenger traffic (up by 6.0%), especially from Asia-Pacific countries. The region will continue to contribute significantly to passenger traffic, supported by the expansion of low-cost carriers, visa-on-arrivals, increasing purchasing power, and favorable exchange rates. Chinese tourists buying luxury items away from their home country and increasing spend per passenger at airports are factors behind this uplift.

 

Market Forecast: Global Airport Retailing

Report Information:
Price:
 $4,950 (Single User License)
Published: May 2017
Publisher: GlobalData
Report Format: electronic pdf